Lipid entity |
Cholesterol |
|
Activity regulation [8,9] |
Activity and changes in conformation [10], Modulation of substrate binding affinity [11] |
Channel inhibition [12] |
Activation [13], Signalling [14,15], Stability [16,17], Allosteric regulation [18], Lower affinity ligand binding [17], Oligomerisation [19,20,21,22,23] |
|
PA |
|
|
|
Activity [24] |
Stabilisation [25] |
|
PE |
|
Dimer formation and function [26], Dimer formation [27], conformer stability [28] |
|
Conformer stabilisation and channel desensitisation [29] |
Agonist and antagonist binding affinities [30], Increase G protein coupling [31,32] |
Protein assembly [33] |
PC |
|
|
|
|
Dimerisation [34], β-arrestin interaction and function [35], Increase G protein coupling [31] |
|
PG |
|
Oligomerisation and function [36] |
|
Conformer stabilisation and channel desensitisation [37] |
Increase G protein coupling [30,38], Active conformer stability [39], β-arrestin interaction and function [35], Decrease G protein coupling [31] |
|
PS |
|
Dimer formation [27], |
|
|
Stabilisation [25], Dimerisation [34], Decrease G protein coupling [31] |
|
PI |
|
Dimer formation and function [26], Possible stabilisation [27] |
|
|
|
|
PtdIns(4,5)P2
|
|
Possible dimer stabilisation [40,41], |
|
Activation [42,43], Inactive conformer stability [44] |
Active conformer stability [25,45], Increase G protein interaction [25], β-arrestin interaction and complex stability [46], Important for G protein recruitment [47] |
|
Glycolipids and sphingolipids |
|
|
|
|
Ligand binding [48,49], Signalling [48], Allostery [47] |
|
Cardiolipin |
Oligomer stabilisation [50] |
Oligomerisation [51], Allosteric regulation [52] |
|
|
|
|
DHA and unsaturated tails |
|
|
|
|
Active conformer stability [53,54], Increase G protein coupling [53], Partitioning to lipid rafts [55], Oligomerisation [34,56] |
|
Saturated tails |
|
|
|
|
Dimerisation and function [57] |
|